Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 117(39): 24258-24268, 2020 09 29.
Artículo en Inglés | MEDLINE | ID: mdl-32913056

RESUMEN

The small GTPase KRAS is localized at the plasma membrane where it functions as a molecular switch, coupling extracellular growth factor stimulation to intracellular signaling networks. In this process, KRAS recruits effectors, such as RAF kinase, to the plasma membrane where they are activated by a series of complex molecular steps. Defining the membrane-bound state of KRAS is fundamental to understanding the activation of RAF kinase and in evaluating novel therapeutic opportunities for the inhibition of oncogenic KRAS-mediated signaling. We combined multiple biophysical measurements and computational methodologies to generate a consensus model for authentically processed, membrane-anchored KRAS. In contrast to the two membrane-proximal conformations previously reported, we identify a third significantly populated state using a combination of neutron reflectivity, fast photochemical oxidation of proteins (FPOP), and NMR. In this highly populated state, which we refer to as "membrane-distal" and estimate to comprise ∼90% of the ensemble, the G-domain does not directly contact the membrane but is tethered via its C-terminal hypervariable region and carboxymethylated farnesyl moiety, as shown by FPOP. Subsequent interaction of the RAF1 RAS binding domain with KRAS does not significantly change G-domain configurations on the membrane but affects their relative populations. Overall, our results are consistent with a directional fly-casting mechanism for KRAS, in which the membrane-distal state of the G-domain can effectively recruit RAF kinase from the cytoplasm for activation at the membrane.


Asunto(s)
Proteínas Proto-Oncogénicas p21(ras)/metabolismo , Quinasas raf/metabolismo , Membrana Celular/metabolismo , Simulación de Dinámica Molecular
2.
Proc Natl Acad Sci U S A ; 109(18): 6898-903, 2012 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-22509046

RESUMEN

HA22 is a recombinant immunotoxin composed of an anti-CD22 Fv fused to a portion of Pseudomonas exotoxin A. HA22 produced a high rate of complete remissions in drug-resistant hairy cell leukemia and has a lower response rate in pediatric acute lymphoblastic leukemia (ALL). To understand why patients with ALL have poorer responses, we isolated an ALL cell line that is resistant to killing by HA22. The resistance is unstable; without HA22 the cells revert to HA22 sensitivity in 4 mo. We showed that in the resistant cell line, HA22 is unable to ADP ribosylate and inactivate elongation factor-2 (EF2), owing to a low level of DPH4 mRNA and protein, which prevents diphthamide biosynthesis and renders EF2 refractory to HA22. Analysis of the promoter region of the DPH4 gene shows that the CpG island was hypomethylated in the HA22-sensitive cells, heavily methylated in the resistant cells, and reverted to low methylation in the revertant cells. Our data show that immunotoxin resistance is associated with reversible CpG island methylation and silencing of DPH4 gene transcription. Incubation of sensitive cells with the methylation inhibitor 5-azacytidine prevented the emergence of resistant cells, suggesting that this agent in combination with HA22 may be useful in the treatment of some cases of ALL.


Asunto(s)
Toxinas Bacterianas/farmacología , Metilación de ADN , Exotoxinas/farmacología , Proteínas del Choque Térmico HSP40/genética , Inmunotoxinas/farmacología , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Regiones Promotoras Genéticas , Azacitidina/farmacología , Secuencia de Bases , Línea Celular Tumoral , Islas de CpG , Metilación de ADN/efectos de los fármacos , ADN de Neoplasias/genética , ADN de Neoplasias/metabolismo , Resistencia a Antineoplásicos/efectos de los fármacos , Resistencia a Antineoplásicos/genética , Humanos , Datos de Secuencia Molecular , Factor 2 de Elongación Peptídica/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , ARN Neoplásico/genética , ARN Neoplásico/metabolismo , Lectina 2 Similar a Ig de Unión al Ácido Siálico/inmunología
3.
J Biol Chem ; 288(17): 12305-12, 2013 Apr 26.
Artículo en Inglés | MEDLINE | ID: mdl-23486472

RESUMEN

HA22 is a recombinant immunotoxin that kills CD22-expressing cells by ADP-ribosylating and inactivating elongation factor-2 (EF2). HA22 is composed of an Fv that binds to CD22 fused to a portion of Pseudomonas exotoxin A. HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with acute lymphoblastic leukemia. To understand why some patients do not respond to HA22, we isolated an HA22-resistant lymphoma cell line and showed that resistance was due to the inability of HA22 to ADP-ribosylate and inactivate EF2. We analyzed the diphthamide synthesis genes and found that the WDR85 gene was deleted. We show that WDR85 knockdown conferred HA22 resistance to sensitive cells and that sensitivity was restored by introduction of a WDR85 cDNA into resistant cells. Analysis of EF2 in the mutant cells revealed a novel form of diphthamide with an additional methyl group that prevented ADP-ribosylation and inactivation of EF2. The abnormal methylation appeared to be catalyzed by DPH5. Inactivation of the WDR85 gene could be a mechanism of immunotoxin resistance in patients undergoing immunotoxin therapy.


Asunto(s)
Resistencia a Antineoplásicos , Eliminación de Gen , Histidina/análogos & derivados , Inmunotoxinas/farmacología , Linfoma/metabolismo , Proteínas de Neoplasias/metabolismo , Factor 2 de Elongación Peptídica/metabolismo , Proteínas , Hidrolasas de Éster Carboxílico , Línea Celular Tumoral , Histidina/genética , Histidina/metabolismo , Humanos , Linfoma/tratamiento farmacológico , Linfoma/genética , Metilación/efectos de los fármacos , Metiltransferasas/genética , Metiltransferasas/metabolismo , Proteínas de Neoplasias/genética , Factor 2 de Elongación Peptídica/genética
4.
J Biol Chem ; 288(25): 18093-103, 2013 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-23649624

RESUMEN

Interleukin-15 (IL-15), a 114-amino acid cytokine related to IL-2, regulates immune homeostasis and the fate of many lymphocyte subsets. We reported that, in the blood of mice and humans, IL-15 is present as a heterodimer associated with soluble IL-15 receptor α (sIL-15Rα). Here, we show efficient production of this noncovalently linked but stable heterodimer in clonal human HEK293 cells and release of the processed IL-15·sIL-15Rα heterodimer in the medium. Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites. Administration of the IL-15·sIL-15Rα heterodimer reconstituted from purified subunits resulted in sustained plasma IL-15 levels and in robust expansion of NK and T cells in mice, demonstrating pharmacokinetics and in vivo bioactivity superior to single chain IL-15. These identified properties of heterodimeric IL-15 provide a strong rationale for the evaluation of this molecule for clinical applications.


Asunto(s)
Subunidad alfa del Receptor de Interleucina-15/metabolismo , Interleucina-15/metabolismo , Complejos Multiproteicos/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión/genética , Proliferación Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Femenino , Glicosilación , Células HEK293 , Humanos , Immunoblotting , Interleucina-15/química , Interleucina-15/genética , Subunidad alfa del Receptor de Interleucina-15/química , Subunidad alfa del Receptor de Interleucina-15/genética , Células Asesinas Naturales/citología , Células Asesinas Naturales/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Complejos Multiproteicos/administración & dosificación , Complejos Multiproteicos/farmacocinética , Unión Proteica , Multimerización de Proteína , Proteolisis , Solubilidad , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Linfocitos T/citología , Linfocitos T/efectos de los fármacos
5.
Pathol Int ; 62(1): 28-35, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22192801

RESUMEN

To date, most of the proteomic analyses on lung cancer tissue samples have been performed using surgical specimens, which are obtained after a diagnosis is made. To determine if a proteomic signature obtained from bronchoscopic biopsy samples could be found to assist with diagnosis, 50 lung cancer bronchoscopic biopsy samples and 13 adjacent normal lung tissue samples were analyzed using histology-directed, matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS). Lung tissue samples were cryosectioned, and sinapinic acid was robotically deposited on areas of each tissue section enriched in epithelial cells, either tumor or normal. Mass spectra were acquired using a MALDI-time of flight instrument. Small cell lung cancers (SCLCs) demonstrated clearly different protein profiles from normal lung tissue and from non-small cell lung cancers (NSCLCs). Calcyclin (m/z= 10,094.7) was identified to be underexpressed in small cell lung cancers, as compared with non-small cell lung cancers and normal lung tissue. An immunohistochemistry study using 152 NSCLCs and 21 SCLCs confirmed significantly reduced calcyclin stain in SCLCs. Thus, protein profiles obtained from bronchoscopic biopsy samples via MALDI MS distinguish cancerous epithelium from normal lung tissue and between NSCLCs and SCLCs.


Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Neoplasias Pulmonares/diagnóstico , Proteínas S100/metabolismo , Carcinoma Pulmonar de Células Pequeñas/diagnóstico , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Adenocarcinoma del Pulmón , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Pulmón de Células no Pequeñas/patología , Femenino , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Proteínas de Neoplasias/análisis , Proteómica/métodos , Proteína A6 de Unión a Calcio de la Familia S100 , Sensibilidad y Especificidad , Carcinoma Pulmonar de Células Pequeñas/patología
6.
Plants (Basel) ; 11(19)2022 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-36235471

RESUMEN

A model of rhizosphere priming effect under impact of root exudate input into rhizosphere soil was developed as an important process of the plant-soil interaction. The model was based on the concept of nitrogen (N) mining, compensating for the N scarcity in exudates for microbial growth by accelerating SOM mineralisation. In the model, N deficiency for microbial growth is covered ("mined") by the increased SOM mineralisation depending on the C:N ratio of the soil and exudates. The new aspect in the model is a food web procedure, which calculates soil fauna feeding on microorganisms, the return of faunal by-products to SOM and mineral N production for root uptake. The model verification demonstrated similar magnitude of the priming effect in simulations as in the published experimental data. Model testing revealed high sensitivity of the simulation results to N content in exudates. Simulated CO2 emission from the priming can reach 10-40% of CO2 emission from the whole Ah horizon of boreal forest soil depending on root exudation rates. This modeling approach with including food web activity allows quantifying wider aspects of the priming effect functioning including ecologically important available N production.

7.
Blood ; 113(16): 3792-800, 2009 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-18988862

RESUMEN

Immunotoxins based on Pseudomonas exotoxin A (PE) are promising anticancer agents that combine a variable fragment (Fv) from an antibody to a tumor-associated antigen with a 38-kDa fragment of PE (PE38). The intoxication pathway of PE immunotoxins involves receptor-mediated internalization and trafficking through endosomes/lysosomes, during which the immunotoxin undergoes important proteolytic processing steps but must otherwise remain intact for eventual transport to the cytosol. We have investigated the proteolytic susceptibility of PE38 immunotoxins to lysosomal proteases and found that cleavage clusters within a limited segment of PE38. We subsequently generated mutants containing deletions in this region using HA22, an anti-CD22 Fv-PE38 immunotoxin currently undergoing clinical trials for B-cell malignancies. One mutant, HA22-LR, lacks all identified cleavage sites, is resistant to lysosomal degradation, and retains excellent biologic activity. HA22-LR killed chronic lymphocytic leukemia cells more potently and uniformly than HA22, suggesting that lysosomal protease digestion may limit immunotoxin efficacy unless the susceptible domain is eliminated. Remarkably, mice tolerated doses of HA22-LR at least 10-fold higher than lethal doses of HA22, and these higher doses exhibited markedly enhanced antitumor activity. We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins.


Asunto(s)
ADP Ribosa Transferasas/farmacología , Anticuerpos Monoclonales/farmacología , Toxinas Bacterianas/farmacología , Exotoxinas/farmacología , Región Variable de Inmunoglobulina/farmacología , Inmunotoxinas/farmacología , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Lectina 2 Similar a Ig de Unión al Ácido Siálico , Factores de Virulencia/farmacología , Ensayos Antitumor por Modelo de Xenoinjerto , ADP Ribosa Transferasas/efectos adversos , ADP Ribosa Transferasas/genética , ADP Ribosa Transferasas/farmacocinética , Animales , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/farmacocinética , Toxinas Bacterianas/efectos adversos , Toxinas Bacterianas/genética , Toxinas Bacterianas/farmacocinética , Ensayos Clínicos como Asunto , Endosomas/metabolismo , Exotoxinas/efectos adversos , Exotoxinas/genética , Exotoxinas/farmacocinética , Femenino , Humanos , Región Variable de Inmunoglobulina/efectos adversos , Región Variable de Inmunoglobulina/genética , Inmunotoxinas/efectos adversos , Inmunotoxinas/genética , Inmunotoxinas/farmacocinética , Leucemia Linfocítica Crónica de Células B/metabolismo , Lisosomas/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Mutación , Factores de Virulencia/efectos adversos , Factores de Virulencia/genética , Factores de Virulencia/farmacocinética , Exotoxina A de Pseudomonas aeruginosa
8.
J Proteome Res ; 9(8): 4123-30, 2010 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-20557134

RESUMEN

To date, proteomic analyses on gastrointestinal cancer tissue samples have been performed using surgical specimens only, which are obtained after a diagnosis is made. To determine if a proteomic signature obtained from endoscopic biopsy samples could be found to assist with diagnosis, frozen endoscopic biopsy samples collected from 63 gastric cancer patients and 43 healthy volunteers were analyzed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. A statistical classification model was developed to distinguish tumor from normal tissues using half the samples and validated with the other half. A protein profile was discovered consisting of 73 signals that could classify 32 cancer and 22 normal samples in the validation set with high predictive values (positive and negative predictive values for cancer, 96.8% and 91.3%; sensitivity, 93.8%; specificity, 95.5%). Signals overexpressed in tumors were identified as alpha-defensin-1, alpha-defensin-2, calgranulin A, and calgranulin B. A protein profile was also found to distinguish pathologic stage Ia (pT1N0M0) samples (n = 10) from more advanced stage (Ib or higher) tumors (n = 48). Thus, protein profiles obtained from endoscopic biopsy samples may be useful in assisting with the diagnosis of gastric cancer and, possibly, in identifying early stage disease.


Asunto(s)
Biomarcadores de Tumor/análisis , Proteómica/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/metabolismo , Biopsia , Estudios de Casos y Controles , Defensinas/metabolismo , Gastroscopía/métodos , Humanos , Complejo de Antígeno L1 de Leucocito/metabolismo , Modelos Estadísticos , Sensibilidad y Especificidad , Neoplasias Gástricas/patología
9.
Chembiochem ; 11(3): 345-50, 2010 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-20052708

RESUMEN

The human epidermal growth factor receptors, EGFR and HER2, are members of the EGFR family of cell-surface receptors/tyrosine kinases. EGFR- and HER2-positive cancers represent a more aggressive disease with greater likelihood of recurrence, poorer prognosis, and decreased survival rate, compared to EGFR- or HER2-negative cancers. The details of HER2 proto-oncogenic functions are not deeply understood, partially because of a restricted availability of tools for EGFR and HER2 detection (A. Sorkin and L. K. Goh, Exp. Cell Res. 2009, 315, 683-696). We have created photostable and relatively simple-to-produce imaging probes for in vitro staining of EGFR and HER2. These new reagents, called affiprobes, consist of a targeting moiety, a HER2- or EGFR-specific Affibody molecule, and a fluorescent moiety, mCherry (red) or EGFP (green). Our flow cytometry and confocal microscopy experiments demonstrated high specificity and signal/background ratio of affiprobes. Affiprobes are able to stain both live cells and frozen tumor xenograph sections. This type of optical probe can easily be extended for targeting other cell-surface antigens/ receptors.


Asunto(s)
Receptores ErbB/análisis , Proteínas Luminiscentes/genética , Sondas Moleculares/química , Receptor ErbB-2/análisis , Proteínas Recombinantes de Fusión/química , Animales , Bencimidazoles/química , Línea Celular Tumoral , Receptores ErbB/genética , Receptores ErbB/metabolismo , Citometría de Flujo , Colorantes Fluorescentes , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Proteínas Luminiscentes/química , Proteínas Luminiscentes/metabolismo , Ratones , Microscopía Confocal , Receptor ErbB-2/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Trasplante Heterólogo , Proteína Fluorescente Roja
10.
Biomed Res Int ; 2020: 1024096, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32566648

RESUMEN

Experimental research results of hydrodynamic noise of pulsating flow through a bileaflet mechanical mitral valve are presented. The pulsating flow of pure water corresponds to the diastolic mode of the cardiac rhythm heart. The valve was located between the model of the left atrium and the model of the left ventricle of the heart. A coordinate device, on which a block of miniature sensors of absolute pressure and pressure fluctuations was installed, was located inside the model of the left ventricle. It is found that the hydrodynamic noise of the pulsating side jet of the semiclosed valve is higher than for the open valve. The pressure fluctuation levels gradually decrease with the removal from the mitral valve. It is established that at the second harmonic of the pulsating flow frequency, the spectral levels of the hydrodynamic noise of the semiclosed bileaflet mechanical mitral valve are almost 5 times higher than the open valve. With the removal from the mitral valve, spectral levels of hydrodynamic noise are decreased, especially strongly at the frequency of the pulsating water flow and its higher harmonics.


Asunto(s)
Prótesis Valvulares Cardíacas , Hidrodinámica , Válvula Mitral/fisiología , Modelos Cardiovasculares , Función Atrial/fisiología , Diástole/fisiología , Humanos , Ruido , Diseño de Prótesis/métodos , Flujo Pulsátil/fisiología , Función Ventricular/fisiología
11.
J Mt Sci ; 17(10): 2459-2484, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33052199

RESUMEN

At the end of October 2018, a storm of unprecedented strength severely damaged the forests of the eastern sector of the Italian Alps. The affected forest area covers 42,500 ha. The president of one of the damaged regions asked for help from the University of Padua. After eight months of discussion, the authors of this article wrote a consensus text. The sometimes asper debate brought to light some crucial aspects: 1) even experienced specialists may have various opinions based on scientific knowledge that lead to conflicting proposals for action. For some of them there is evidence that to restore a destroyed natural environment it is more judicious to do nothing; 2) the soil corresponds to a living structure and every ecosystem's management should be based on it; 3) faced with a catastrophe, people and politicians find themselves unarmed, also because they rarely have the scientific background to understand natural processes. Yet politicians are the only persons who make the key decisions that drive the economy in play and therefore determine the near future of our planet. This article is an attempt to respond directly to a governor with a degree in animal production science, who formally and prudently asked a university department called "Land, Environment, Agriculture and Forestry" for help before taking decisions; 4) the authors also propose an artistic interpretation of facts (uncontrolled storm) and conclusions (listen to the soil). Briefly, the authors identify the soil as an indispensable source for the renewal of the destroyed forest, give indications on how to prepare a map of the soils of the damaged region, and suggest to anchor on this soil map a series of silvicultural and soil management actions that will promote the soil conservation and the faster recovery of the natural dynamic stability and resilience. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available for this article at 10.1007/s11629-019-5890-0 and is accessible for authorized users.

12.
Biochem Biophys Res Commun ; 380(3): 508-13, 2009 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-19250639

RESUMEN

CAPC (also known as LRRC26) is a new gene with restricted expression in normal tissues, and with expression in many cancers and cancer cell lines. We have identified and characterized a short-transcript of CAPC (S-CAPC). The nucleotide sequence analysis of CAPC mRNA showed that the transcription for S-CAPC starts at position +610 on the L-CAPC transcript. Interestingly, no translation initiation codon 'AUG' is present in this transcript. To determine if a non-AUG start site is utilized, the S-CAPC sequence was cloned into an expression vector with C-terminal myc and histidine tags, and transfected into 293T cells. Western blot and MALDI-TOF MS analysis on purified S-CAPC gave two distinct peaks at approximately 7.5 kDa. N-terminal amino acid sequencing of the purified 7.5 kDa protein product indicated that translation starts at the codon for cysteine on the S


Asunto(s)
Codón Iniciador/metabolismo , Proteínas de Neoplasias/biosíntesis , Neoplasias/metabolismo , Iniciación de la Cadena Peptídica Traduccional , Línea Celular Tumoral , Humanos , Proteínas de Neoplasias/genética , Neoplasias/genética , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/genética , ARN Mensajero/metabolismo , Análisis de Secuencia de Proteína , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Transcripción Genética
13.
Clin Cancer Res ; 14(12): 3840-9, 2008 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-18559604

RESUMEN

PURPOSE: HER2 overexpression has been associated with a poor prognosis and resistance to therapy in breast cancer patients. We are developing molecular probes for in vivo quantitative imaging of HER2 receptors using near-infrared (NIR) optical imaging. The goal is to provide probes that will minimally interfere with the studied system, that is, whose binding does not interfere with the binding of the therapeutic agents and whose effect on the target cells is minimal. EXPERIMENTAL DESIGN: We used three different types of HER2-specific Affibody molecules [monomer ZHER2:342, dimer (ZHER2:477)2, and albumin-binding domain-fused-(ZHER2:342)2] as targeting agents and labeled them with Alexa Fluor dyes. Trastuzumab was also conjugated, using commercially available kits, as a standard control. The resulting conjugates were characterized in vitro by toxicity assays, Biacore affinity measurements, flow cytometry, and confocal microscopy. Semiquantitative in vivo NIR optical imaging studies were carried out using mice with s.c. xenografts of HER2-positive tumors. RESULTS: The HER2-specific Affibody molecules were not toxic to HER2-overexpressing cells and their binding to HER2 did interfere with neither binding nor effectives of trastuzumab. The binding affinities and specificities of the Affibody-Alexa Fluor fluorescent conjugates to HER2 were unchanged or minimally affected by the modifications. Pharmacokinetics and biodistribution studies showed the albumin-binding domain-fused-(ZHER2:342)2-Alexa Fluor 750 conjugate to be an optimal probe for optical imaging of HER2 in vivo. CONCLUSION: Our results suggest that Affibody-Alexa Fluor conjugates may be used as a specific NIR probe for the noninvasive semiquantitative imaging of HER2 expression in vivo.


Asunto(s)
Genes erbB-2 , Neoplasias/diagnóstico , Proteínas Recombinantes de Fusión , Espectroscopía Infrarroja Corta/métodos , Albúminas/metabolismo , Animales , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Antineoplásicos/uso terapéutico , Femenino , Colorantes Fluorescentes , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias/genética , Neoplasias/terapia , Estructura Terciaria de Proteína , Proteínas Recombinantes de Fusión/química , Trastuzumab , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
14.
Springerplus ; 5: 78, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26844025

RESUMEN

In the era of Big Data, it is almost impossible to completely restrict access to primary non-aggregated statistical data. However, risk of violating privacy of individual respondents and groups of respondents by analyzing primary data has not been reduced. There is a need in developing subtler methods of data protection to come to grips with these challenges. In some cases, individual and group privacy can be easily violated, because the primary data contain attributes that uniquely identify individuals and groups thereof. Removing such attributes from the dataset is a crude solution and does not guarantee complete privacy. In the field of providing individual data anonymity, this problem has been widely recognized, and various methods have been proposed to solve it. In the current work, we demonstrate that it is possible to violate group anonymity as well, even if those attributes that uniquely identify the group are removed. As it turns out, it is possible to use third-party data to build a fuzzy model of a group. Typically, such a model comes in a form of a set of fuzzy rules, which can be used to determine membership grades of respondents in the group with a level of certainty sufficient to violate group anonymity. In the work, we introduce an evolutionary computing based method to build such a model. We also discuss a memetic approach to protecting the data from group anonymity violation in this case.

15.
Mol Cancer Ther ; 15(7): 1648-55, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27196771

RESUMEN

Mesothelin (MSLN) is a differentiation antigen that is highly expressed in many epithelial cancers. MSLN is an important therapeutic target due to its high expression in cancers and limited expression in normal human tissues. Although it has been assumed that shed antigen is a barrier to immunotoxin action, a modeling study predicted that shed MSLN may enhance the action of MSLN-targeting recombinant immunotoxins such as SS1P and similar therapeutics by facilitating their redistribution within tumors. We aimed to determine whether shed MSLN enhances or reduces the antitumor effect of MSLN-targeting immunotoxins SS1P and RG7787. We engineered a cell line, A431/G9 (TACE mutant) that expresses a mutant form of MSLN in which the TNF-converting enzyme protease site is replaced with GGGS. We compared the response of the TACE-mutant cells with immunotoxins SS1P and RG7787 with that of the parental A431/H9 cell line. We show that TACE-mutant cells shed 80% less MSLN than A431/H9 cells, that TACE-mutant cells show a 2- to 3-fold increase in MSLN-targeted immunotoxin uptake, and that they are about 5-fold more sensitive to SS1P killing in cell culture. Tumors with reduced shedding respond significantly better to treatment with SS1P and RG7787. Our data show that MSLN shedding is an impediment to the antitumor activity of SS1P and RG7787. Approaches that decrease MSLN shedding could enhance the efficacy of immunotoxins and immunoconjugates targeting MSLN-expressing tumors. Mol Cancer Ther; 15(7); 1648-55. ©2016 AACR.


Asunto(s)
Antineoplásicos/farmacología , Membrana Celular/metabolismo , Proteínas Ligadas a GPI/antagonistas & inhibidores , Proteínas Ligadas a GPI/metabolismo , Inmunotoxinas/farmacología , Proteínas Recombinantes de Fusión/farmacología , Animales , Anticuerpos Monoclonales , Línea Celular Tumoral , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Resistencia a Antineoplásicos/genética , Proteínas Ligadas a GPI/genética , Expresión Génica , Humanos , Mesotelina , Mutación , Ensayos Antitumor por Modelo de Xenoinjerto
16.
Comput Methods Programs Biomed ; 134: 179-86, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27480742

RESUMEN

BACKGROUND AND OBJECTIVE: Nocturnal hypoglycemia (NH) is common in patients with insulin-treated diabetes. Despite the risk associated with NH, there are only a few methods aiming at the prediction of such events based on intermittent blood glucose monitoring data and none has been validated for clinical use. Here we propose a method of combining several predictors into a new one that will perform at the level of the best involved one, or even outperform all individual candidates. METHODS: The idea of the method is to use a recently developed strategy for aggregating ranking algorithms. The method has been calibrated and tested on data extracted from clinical trials, performed in the European FP7-funded project DIAdvisor. Then we have tested the proposed approach on other datasets to show the portability of the method. This feature of the method allows its simple implementation in the form of a diabetic smartphone app. RESULTS: On the considered datasets the proposed approach exhibits good performance in terms of sensitivity, specificity and predictive values. Moreover, the resulting predictor automatically performs at the level of the best involved method or even outperforms it. CONCLUSION: We propose a strategy for a combination of NH predictors that leads to a method exhibiting a reliable performance and the potential for everyday use by any patient who performs self-monitoring of blood glucose.


Asunto(s)
Diabetes Mellitus Tipo 1/sangre , Hipoglucemia/diagnóstico , Humanos
17.
Expert Rev Proteomics ; 2(1): 139-45, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15966859

RESUMEN

The dramatic progress in mass spectrometry-based methods of protein identification has triggered a new quest for disease-associated biomarkers. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and its variant surface-enhanced laser desorption/ionization mass spectrometry, provide effective means to explore the less studied information slice of the human serum proteome -- low-molecular-weight proteins and peptides. These low-molecular-weight proteins and peptides are promising for the detection of important biomarkers. Due to the significant experimental problems imposed by high-abundance and high-molecular-weight proteins, it is important to effectively remove these species prior to mass spectrometry analysis of the low-molecular-weight serum and plasma proteomes. In this review, the advantages afforded by recently introduced methods for prefractionation of serum, as they pertain to the detection and identification of biomarkers, will be discussed.


Asunto(s)
Biomarcadores/análisis , Proteínas/aislamiento & purificación , Acetonitrilos , Proteínas Sanguíneas/aislamiento & purificación , Cromatografía en Gel , Cromatografía por Intercambio Iónico , Electroforesis en Gel de Poliacrilamida , Perfilación de la Expresión Génica , Espectrometría de Masas , Peso Molecular , Albúmina Sérica/aislamiento & purificación , Solventes , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
18.
Cell Signal ; 16(2): 281-6, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14636898

RESUMEN

IL-7 induction of protein tyrosine phosphorylation was examined in an IL-7-dependent thymocyte cell line, D1, which was generated from a p53-/- mouse. Anti-phosphotyrosine antibody was used both to immunoprecipitate and Western blot, and showed that IL-7 induced tyrosine phosphorylation of a protein with a molecular weight of approximately 200 kDa. The P200 band was purified by reversed-phase high-performance liquid chromatography. Amino acid sequencing by mass spectrometry revealed three peptides identical to rat clathrin heavy chain (CHC) 1 (192 kDa), and this was confirmed by blotting with an anti-clathrin antibody. Stimulation of normal pro-T cells by IL-7 showed an increased tyrosine phosphorylation of clathrin heavy chain. Tyrosine phosphorylation of clathrin heavy chain was strongly induced by IL-7 and to a lesser extent by IL-4, while no effect could be observed with the cytokines IL-2, IL-9 and IL-15, whose receptors share the gammac chain. Phosphorylation of clathrin heavy chain was found to be sensitive to Jak3 inhibitors but not to Src inhibitors. Clathrin is involved in internalization of many receptors, and its phosphorylation by IL-7 stimulation may affect the internalization of the IL-7 receptor.


Asunto(s)
Cadenas Pesadas de Clatrina/metabolismo , Interleucina-4/farmacología , Interleucina-7/farmacología , Linfocitos T/metabolismo , Tirosina/metabolismo , Animales , Inhibidores Enzimáticos/farmacología , Interleucinas/farmacología , Janus Quinasa 3 , Espectrometría de Masas , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fosforilación/efectos de los fármacos , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/metabolismo , Proteína p53 Supresora de Tumor/genética , Familia-src Quinasas/antagonistas & inhibidores , Familia-src Quinasas/metabolismo
19.
Clin Cancer Res ; 9(8): 3115-23, 2003 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-12912963

RESUMEN

PURPOSE: Increasing evidence suggests that interaction between the chemoattractant CXCL12/stromal cell-derived factor-1alpha and its receptor CXCR4 plays a pivotal role in the metastasis of various tumors. Our previous studies showed that multi-component Chinese herbal medicines inhibited the effects of CXCL12/CXCR4. As a result of sequential chromatographic fractionation of one herbal medicine ingredient, Lianqiao (fruit of Forsythia suspensa), we observed that tannins were, at least in part, responsible for this activity. The aim of this study was to assess the anti-CXCL12/CXCR4 activity of a commercial tannic acid and evaluate its potential to inhibit tumor cell migration and angiogenesis in vitro. EXPERIMENTAL DESIGN: The inhibitory effect of tannic acid on CXCL12/CXCR4 was measured by chemotaxis assay, ligand binding assay, and fluorescence-activated cell sorter analysis. The antiangiogenic effect of tannic acid was assessed by in vitro endothelial cell tube formation. RESULTS: Tannic acid, at nontoxic concentrations, specifically inhibited CXCL12-induced human monocyte migration (IC(50), 7.5 micro g/ml) but did not inhibit CCL2-, CCL3-, CCL5-, formylmethionylleucylphenylalanine (fMLP)-, or C5a-induced migration. The compound markedly blocked CXCL12 binding to THP-1 cells (IC(50), 0.36 micro g/ml). Tannic acid also inhibited CXCL12-induced, but not epidermal growth factor-induced, migration of MDA 231 breast tumor cells. Additionally, 0.5 micro g/ml of tannic acid selectively inhibited CXCL12-mediated, but not basic fibroblast growth factor- or endothelial cell growth supplement-mediated, bovine aorta endothelial cell capillary tube formation. CONCLUSION: These studies indicate that tannic acid is a novel selective CXCL12/CXCR4 antagonist and consequently may provide a mechanistic basis for the reported antitumor and anti-inflammatory properties of tannic acid.


Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Quimiocinas CXC/antagonistas & inhibidores , Taninos Hidrolizables/uso terapéutico , Receptores CXCR4/antagonistas & inhibidores , Animales , Planta del Astrágalo , Astragalus propinquus , Capilares/metabolismo , Bovinos , División Celular , Línea Celular , Línea Celular Tumoral , Movimiento Celular , Separación Celular , Células Cultivadas , Quimiocina CXCL12 , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/uso terapéutico , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Citometría de Flujo , Forsythia/metabolismo , Humanos , Taninos Hidrolizables/metabolismo , Concentración 50 Inhibidora , Ligandos , Lonicera , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Neovascularización Patológica , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Estructuras de las Plantas , Unión Proteica
20.
Sci Rep ; 5: 15916, 2015 Nov 02.
Artículo en Inglés | MEDLINE | ID: mdl-26522388

RESUMEN

Prenylated proteins play key roles in several human diseases including cancer, atherosclerosis and Alzheimer's disease. KRAS4b, which is frequently mutated in pancreatic, colon and lung cancers, is processed by farnesylation, proteolytic cleavage and carboxymethylation at the C-terminus. Plasma membrane localization of KRAS4b requires this processing as does KRAS4b-dependent RAF kinase activation. Previous attempts to produce modified KRAS have relied on protein engineering approaches or in vitro farnesylation of bacterially expressed KRAS protein. The proteins produced by these methods do not accurately replicate the mature KRAS protein found in mammalian cells and the protein yield is typically low. We describe a protocol that yields 5-10 mg/L highly purified, farnesylated, and methylated KRAS4b from insect cells. Farnesylated and methylated KRAS4b is fully active in hydrolyzing GTP, binds RAF-RBD on lipid Nanodiscs and interacts with the known farnesyl-binding protein PDEδ.


Asunto(s)
Lípidos/fisiología , Prenilación de Proteína/fisiología , Proteínas Proto-Oncogénicas p21(ras)/metabolismo , Animales , Biofisica/métodos , Membrana Celular/metabolismo , Células Cultivadas , Guanosina Trifosfato/metabolismo , Humanos , Insectos/metabolismo , Metilación , Unión Proteica/fisiología , Quinasas raf/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA